Page last updated: 2024-08-24

atorvastatin and etidronate

atorvastatin has been researched along with etidronate in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Barut, A; Sarikaya, S; Tanriverdi, HA1
Baytur, Y; Demir, BC; Gumuser, G; Inceboz, U; Ozbilgin, K; Uyar, Y1
Akiyoshi, T; Anami, S; Matsuyama, K; Matzno, S; Nakabayashi, T; Nishiguchi, T1
Furusawa, T; Inazu, T; Kawahara, T; Nishikawa, M; Suzuki, G1
Inazu, T; Kawahara, C; Kawahara, T; Nishikawa, M; Sakai, K; Suzuki, G1
Kawahara, T; Suzuki, G1

Reviews

1 review(s) available for atorvastatin and etidronate

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

3 trial(s) available for atorvastatin and etidronate

ArticleYear
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
    European journal of obstetrics, gynecology, and reproductive biology, 2005, May-01, Volume: 120, Issue:1

    Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Pyrroles; Risedronic Acid

2005
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
    Circulation, 2013, Jun-11, Volume: 127, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atorvastatin; Bone Density; Calcinosis; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Organ Specificity; Plaque, Atherosclerotic; Prospective Studies; Pyrroles

2013
[Series: Clinical study from Japan and its reflections; atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Feb-10, Volume: 103, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aorta; Atorvastatin; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk

2014

Other Studies

5 other study(ies) available for atorvastatin and etidronate

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
    Maturitas, 2009, Jul-20, Volume: 63, Issue:3

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density; Bone Density Conservation Agents; Clomiphene; Estrogens; Etidronic Acid; Female; Femur; Heptanoic Acids; Osteoporosis; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid; Selective Estrogen Receptor Modulators; Tibia

2009
Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.
    The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:6

    Topics: Alendronate; Animals; Apoptosis; Atorvastatin; Bone Density Conservation Agents; Caspases; Cell Line; Diphosphonates; DNA Fragmentation; Drug Synergism; Enzyme Activation; Etidronic Acid; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myoblasts, Skeletal; Pyrroles; Rats; Rhabdomyolysis; Risedronic Acid

2009
Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging.
    Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:5

    Topics: Aorta; Atorvastatin; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome

2011